Greg Harrison
Stock Analyst at B of A Securities
(4.51)
# 269
Out of 5,182 analysts
106
Total ratings
58.02%
Success rate
21.12%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $44 → $41 | $24.43 | +67.83% | 10 | Apr 21, 2026 | |
| UTHR United Therapeutics | Maintains: Neutral | $569 → $626 | $566.99 | +10.41% | 6 | Mar 31, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $46 → $51 | $26.99 | +88.96% | 3 | Mar 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $495 → $558 | $426.01 | +30.98% | 8 | Feb 13, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $13.04 | +130.06% | 3 | Oct 27, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $40.81 | -24.04% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $9.52 | +110.08% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $74.52 | -23.51% | 7 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $308.51 | +45.86% | 6 | Aug 1, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $0.35 | +3,056.38% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $8.30 | +321.69% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $37.28 | +47.53% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $51 → $19 | $3.49 | +444.41% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $37.34 | -0.91% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $11.01 | +136.15% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $40.95 | -51.16% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.53 | -1.96% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $29.17 | +37.15% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $68.85 | +8.93% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $13.60 | +32.35% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $33.71 | -64.40% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.21 | +614.29% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.89 | +419.03% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $14.74 | -79.65% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.06 | +6,503.77% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $14.63 | +269.10% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $86.74 | +3.76% | 5 | Mar 14, 2022 |
Agios Pharmaceuticals
Apr 21, 2026
Maintains: Buy
Price Target: $44 → $41
Current: $24.43
Upside: +67.83%
United Therapeutics
Mar 31, 2026
Maintains: Neutral
Price Target: $569 → $626
Current: $566.99
Upside: +10.41%
Mineralys Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $46 → $51
Current: $26.99
Upside: +88.96%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Sector Perform
Price Target: $495 → $558
Current: $426.01
Upside: +30.98%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $13.04
Upside: +130.06%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $40.81
Upside: -24.04%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $9.52
Upside: +110.08%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $74.52
Upside: -23.51%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $308.51
Upside: +45.86%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $0.35
Upside: +3,056.38%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $8.30
Upside: +321.69%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $37.28
Upside: +47.53%
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $3.49
Upside: +444.41%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $37.34
Upside: -0.91%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $11.01
Upside: +136.15%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $40.95
Upside: -51.16%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.53
Upside: -1.96%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $29.17
Upside: +37.15%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $68.85
Upside: +8.93%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $13.60
Upside: +32.35%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $33.71
Upside: -64.40%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.21
Upside: +614.29%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.89
Upside: +419.03%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $14.74
Upside: -79.65%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $1.06
Upside: +6,503.77%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $14.63
Upside: +269.10%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $86.74
Upside: +3.76%